Cytek Biosciences announced that it has opened a new 50,000-square-foot facility in Wuxi, China. This strategic move increases the company’s manufacturing capacity to meet the demand for cell analysis solutions. The Wuxi facility offers vendor relationships and further facilitates Cytek to manufacture its own components. In addition to bolstering Cytek’s manufacturing capabilities, the facility also accommodates Cytek Wuxi operations, research and development, marketing, human resources, and sales teams.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTKB:
- Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
- Cytek Biosciences price target lowered to $10 from $11 at Piper Sandler
- Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
- Cytek Biosciences sees FY24 revenue $203M-$213M, consensus $207.1M
- Cytek Biosciences reports Q4 adjusted EBITDA $11.0M vs. $6.6M last year